Jennifer Juno
🇨🇦 in 🇦🇺 Scientist. Geek. Feminist. She/her. Lab head (viralvaxlab.com) at the Doherty Institute and University of Melbourne, interested in all things CD4/TFH/vaccine and virus-related. I stare at dots a lot.
- Reposted by Jennifer Juno[Not loaded yet]
- Reposted by Jennifer Juno[Not loaded yet]
- Reposted by Jennifer Juno[Not loaded yet]
- Reposted by Jennifer JunoExcited to have our latest research published in @jem.org this week and also highlighted by @natrevimmunol.nature.com @wehi-research.bsky.social @benjbroom.bsky.social
- Future vaccines a step closer. Research from @groomlab.bsky.social, @benjbroom.bsky.social and team use novel approach and mRNA tech to boost stem cell-like memory CD8+ T cells after vaccination. Published in @jem.org www.wehi.edu.au/news/vaccine...
- Fantastic work from @labphan.bsky.social and @mlmunier.bsky.social combining mouse models and clinical studies to understand B cell recall following booster vaccination. Check out the paper and thread below! ⤵️
- Happy #DayofImmunology! Congrats @ramadhenni.bsky.social & Alexandra Carey Hoppé it's out (finally!) @cp-cell.bsky.social! Incredibly grateful to co-leads @mlmunier.bsky.social, Vanessa Venturi & Tony Kelleher & all brilliant folks @garvaninstitute.bsky.social & Kirby Inst. for fantastic collab! 🧵
- Happy to report that Mitchell's paper on CD4 T cells and AIM assays is now available online at Science Advances! www.science.org/doi/10.1126/... Thanks to all our collaborators in @viralvaxlab.bsky.social and @thedohertyinst.bsky.social, including @assocprofashhaque.bsky.social lab
- As a first #ImmunoSky post, I’m excited to share our latest pre-print, by the fantastic Mitchell Zheng! www.biorxiv.org/content/10.1... Our group is interested in virus-specific CD4 T cells, which means we often use in vitro stimulations (like the AIM assay) to find our cells of interest. 🧵 1/9
- Check out the latest from @viralvaxlab.bsky.social postdoc Wen Shi Lee, developing monoclonal antibodies that neutralise the NL63 coronavirus!
Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus www.nature.com/articles/s44...
- Great new story exploring how B cells can recognise glycans (and still get T cell help!) from @precisionvaxlab.bsky.social and team!
- New preprint alert 🚨 My team and I are pleased to share our most recent story about how bacterial pathogen (Streptococcus pyogenes, Strep A) exposure induces antibody responses against glycan and protein antigens. For paper: SSRN ssrn.com/abstract=519... biorxiv : doi: doi.org/10.1101/2025...
- Reposted by Jennifer Juno[Not loaded yet]
- Check out the latest work from @viralvaxlab.bsky.social, now online in @jimmunol.bsky.social!
- New research from @thedohertyinst.bsky.social suggests that receiving multiple doses of a vaccine in the same limb leads to faster antibody development, an important strategy for providing #immunity quickly during a pandemic or disease #outbreak. #ReadTheJI #immunology ow.ly/c28N50VeRGR
- Reposted by Jennifer Juno[Not loaded yet]
- Reposted by Jennifer Juno[Not loaded yet]
- Reposted by Jennifer JunoKicking off the new year searching for a postdoc to join our team @wehi-research.bsky.social Apply now and spread the word
- As a first #ImmunoSky post, I’m excited to share our latest pre-print, by the fantastic Mitchell Zheng! www.biorxiv.org/content/10.1... Our group is interested in virus-specific CD4 T cells, which means we often use in vitro stimulations (like the AIM assay) to find our cells of interest. 🧵 1/9
- 2/9 Recently, though, we’ve been bothered by something we couldn’t explain: we find a lot of Th17-like, CCR6+ SARS-CoV-2 spike-specific CD4 T cells in our AIM assays, but we never see these cells when we use spike-specific class II tetramers. Why?
- Reposted by Jennifer Juno[Not loaded yet]
